These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26517483)

  • 1. Ceftaroline activity on certain respiratory tract and wound infection agents at the minimum inhibitory concentration level.
    Yanik K; Guluzade E; Bilgin K; Karadag A; Eroglu C; Birinci A; Gunaydin M
    J Infect Dev Ctries; 2015 Oct; 9(10):1086-90. PubMed ID: 26517483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
    Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.
    Biedenbach DJ; Iaconis JP; Sahm DF
    J Antimicrob Chemother; 2016 Dec; 71(12):3459-3464. PubMed ID: 27559120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.
    Karlowsky JA; Biedenbach DJ; Bouchillon SK; Hackel M; Iaconis JP; Sahm DF
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):194-9. PubMed ID: 27461798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species.
    Barry AL; Pfaller MA; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):548-53. PubMed ID: 8404918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
    Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.
    Sader HS; Flamm RK; Streit JM; Carvalhaes CG; Mendes RE
    Int J Infect Dis; 2018 Dec; 77():82-86. PubMed ID: 30315990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF; Brown NP; Thornsberry C; Jones ME
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.